Investing.com - Financial Markets Worldwide

Recce Ltd (RCE)

Sydney
Currency in AUD
0.420
-0.010(-2.33%)
Closed·
RCE Scorecard
Full Analysis
Suffers from weak gross profit margins
RCE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
0.4150.430
52 wk Range
0.2750.570
Key Statistics
Edit
Bid/Ask
0.415 / 0.43
Prev. Close
0.43
Open
0.43
Day's Range
0.415-0.43
52 wk Range
0.275-0.57
Volume
76.97K
Average Volume (3m)
137.53K
1-Year Change
-16.67%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RCE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 7
Short term obligations exceed liquid assets
Unlock InvestingPro

Recce Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Recce Ltd Company Profile

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis rapid infusion; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. Recce Pharmaceuticals has strategic partnership with Murdoch Children’s Research Institute for development of the Neisseria gonorrhoeae, Mycobacterium abscessus, and Escherichia coli clinical trials; and cooperative research and development agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to be tested against highly hazardous pathogens. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Industry
Pharmaceuticals
Sector
Healthcare
0
Market
Australia

Compare RCE to Peers and Sector

Metrics to compare
RCE
Peers
Sector
Relationship
P/E Ratio
−6.9x−3.6x−0.6x
PEG Ratio
0.14−0.010.00
Price/Book
−24.9x1.4x2.6x
Price / LTM Sales
13.0x7.1x3.3x
Upside (Analyst Target)
-173.5%38.7%
Fair Value Upside
Unlock18.2%5.1%Unlock

Earnings

Latest Release
Feb 27, 2025
EPS / Forecast
-0.03 / --
Revenue / Forecast
6.95M / --
EPS Revisions
a
a
Unlock
Last 90 days

RCE Income Statement

FAQ

What Stock Exchange Does Recce Trade On?

Recce is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Recce?

The stock symbol for Recce is "RCE."

What Is the Recce Market Cap?

As of today, Recce market cap is 121.46M.

What Is Recce's Earnings Per Share (TTM)?

The Recce EPS (TTM) is -0.09.

From a Technical Analysis Perspective, Is RCE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Recce Stock Split?

Recce has split 0 times.

How Many Employees Does Recce Have?

Recce has 0 employees.

What is the current trading status of Recce (RCE)?

As of 28 Aug 2025, Recce (RCE) is trading at a price of 0.420, with a previous close of 0.43. The stock has fluctuated within a day range of 0.415 to 0.430, while its 52-week range spans from 0.275 to 0.570.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.